What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Bacteria
Paul E. Verweij mainly investigates Microbiology, Aspergillus fumigatus, Aspergillosis, Voriconazole and Itraconazole.
His research is interdisciplinary, bridging the disciplines of Genotype and Microbiology.
His work deals with themes such as Fungi imperfecti, Azole, Azole resistance and Drug resistance, which intersect with Aspergillus fumigatus.
Paul E. Verweij interconnects Internal medicine, Mycosis and Aspergillus in the investigation of issues within Aspergillosis.
His work carried out in the field of Voriconazole brings together such families of science as Pharmacology and Chronic granulomatous disease.
Paul E. Verweij usually deals with Itraconazole and limits it to topics linked to Fluconazole and Amphotericin B deoxycholate.
His most cited work include:
- ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. (751 citations)
- ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013 (543 citations)
- Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. (542 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Microbiology, Aspergillus fumigatus, Aspergillosis, Voriconazole and Aspergillus.
His study in Microbiology concentrates on Itraconazole, Amphotericin B, Antifungal, Broth microdilution and Fungi imperfecti.
His work focuses on many connections between Aspergillus fumigatus and other disciplines, such as Azole, that overlap with his field of interest in Fungicide and Gene.
His studies in Aspergillosis integrate themes in fields like Pathology, Internal medicine, Mycosis and Intensive care medicine.
Paul E. Verweij has researched Voriconazole in several fields, including Echinocandin and Pharmacology.
His studies deal with areas such as Galactomannan and Chronic pulmonary aspergillosis as well as Aspergillus.
He most often published in these fields:
- Microbiology (45.29%)
- Aspergillus fumigatus (35.86%)
- Aspergillosis (34.75%)
What were the highlights of his more recent work (between 2018-2021)?
- Aspergillosis (34.75%)
- Aspergillus fumigatus (35.86%)
- Microbiology (45.29%)
In recent papers he was focusing on the following fields of study:
Paul E. Verweij mostly deals with Aspergillosis, Aspergillus fumigatus, Microbiology, Aspergillus and Azole.
His Aspergillosis research incorporates elements of Internal medicine, Hematological malignancy, Disease, Posaconazole and Intensive care medicine.
His Aspergillus fumigatus study combines topics from a wide range of disciplines, such as Genetics, Gene, Genotype, Fungicide and Azole resistance.
His Microbiology research integrates issues from Cystic fibrosis and Agar.
His work in Aspergillus addresses subjects such as Chronic pulmonary aspergillosis, which are connected to disciplines such as Mutation.
The concepts of his Voriconazole study are interwoven with issues in Amphotericin B, Mortality rate, Luliconazole, Susceptibility testing and Broth microdilution.
Between 2018 and 2021, his most popular works were:
- Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (285 citations)
- COVID-19-associated Pulmonary Aspergillosis. (96 citations)
- Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study (77 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Bacteria
- Gene
His primary areas of study are Aspergillus fumigatus, Aspergillosis, Microbiology, Voriconazole and Internal medicine.
His Aspergillus fumigatus research is multidisciplinary, relying on both Antifungal drug, Itraconazole, Azole and Genotype.
His Aspergillosis research incorporates themes from Coinfection, Ventilator-associated pneumonia, Posaconazole and Aspergillus flavus.
His Microbiology study combines topics in areas such as Infection control, Fungicide and Agar.
The various areas that Paul E. Verweij examines in his Voriconazole study include Disease and Intensive care medicine.
His research investigates the connection with Internal medicine and areas like Galactomannan which intersect with concerns in Allergy, Transplantation, Multicenter study and Gastroenterology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
